Showing 8921-8930 of 21419 results for "".
Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
https://reachmd.com/programs/cme/secondary-stroke-prevention-emerging-role-factor-xi-inhibition/50969/Preventing stroke is critical, but for many patients, the fear of uncontrolled bleeding stands in the way of anticoagulation. What if we didn’t have to choose? Explore the emerging role of Factor XI/XIa inhibition and how it may redefine the balance between thrombosis and hemostasis. You’ll break doSafety of CDK4/6 Inhibitors: Anticipation, Prevention, and Management of Adverse Events
https://reachmd.com/programs/cme/safety-of-cdk46-inhibitors-anticipation-prevention-and-management-of-adverse-events/39799/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
https://reachmd.com/programs/cme/redefining-immunotherapy-access-integrating-subcutaneous-checkpoint-inhibitors-across-solid-tumors/56117/How are SC immune checkpoint inhibitors changing care in solid tumors? Hear a physician–nurse interview and explore implications for your practice.Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
https://reachmd.com/programs/cme/breaking-down-the-benchmarks-pivotal-data-on-first-line-cdk46-inhibitors/39798/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Real-World Impact of Evolocumab on MACE Reduction in ASCVD
https://reachmd.com/clinical-practice/cardiology/real-world-impact-of-evolocumab-on-mace-reduction-in-ascvd/39991/Review real-world data on evolocumab and its association with reduced MACE in patients with established atherosclerotic cardiovascular disease.Treatment Patterns and MRA Use in Patients with HFmrEF/HFpEF: Insights From FRAME-HF and IRIS HF
https://reachmd.com/clinical-practice/cardiology/heart-failure-treatment-trends-insights-from-frame-hf-and-iris-hf/57080/Review ESC Heart Failure 2026 data on treatment patterns and MRA use in HF across the FRAME-HF and IRIS-HF cohorts.Finerenone in HFpEF: Key Insights From ESC HF
https://reachmd.com/clinical-practice/cardiology/finerenone-in-ckm-disease-and-hfpef-key-takeaways-from-esc-hf/49255/Review analyses from ESC Heart Failure 2026 examining finerenone in CKM disease and HFpEF, including outcomes in undiagnosed CKD.When Topicals Fail: The New IPC Consensus Every Clinician Should Know
https://reachmd.com/programs/cme/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/Review IPC’s 2025 consensus guidance on reclassifying psoriasis severity and redefining failure of topical therapies.RSV in Infants and Young Children: Are You Taking It Seriously Enough?
https://reachmd.com/programs/cme/RSV-in-Infants-and-Young-Children-Are-You-Taking-It-Seriously-Enough/39306/Explore RSV prevention strategies in infants, including maternal immunization and monoclonal antibodies, aligned with current AAP guidelines.From Pixels to Practice: Advancing HCM Care With Multimodality Imaging
https://reachmd.com/programs/cme/from-pixels-to-practice-advancing-hcm-care-with-multimodality-imaging/39877/Explore how multimodality imaging advances diagnosis, treatment selection, and monitoring in hypertrophic cardiomyopathy care.